Proactive Investors - Run By Investors For Investors

Bid battle breaks out for UAE hospital group Al Noor

Al Noor has received an approach from VPS Healthcare
Bid battle breaks out for UAE hospital group Al Noor
Al Noor has made its own agreed bid for Mediclinic

A bid battle has reportedly broken out for United Arab Emirates private health group Al Noor Hospitals (LON:ANH).

Al Noor said in a statement that it had received a "highly preliminary" indication of interest from Abu Dhabi-based VPS Healthcare (VPSH), however no formal proposal or indicative terms were received.

It has been reported that another Abu Dhabi-based group, London-listed NMC Health (LON:NMC), is considering a rival offer.

The news comes after Al Noor agreed a takeover of South African-owned Mediclinic International on October 14.

Al Noor released a statement on Tuesday after comments made by chief executive Ronald Lavater to UAE newspaper The National.

"We've received another expression of interest. I cannot identify the source of the potential bidder, nor say whether or not it will amount to a bid," Reuters reported Lavater as telling the newspaper.

If the Mediclinic acquisition went through, the enlarged group would be the third largest private healthcare provider in revenue terms in South Africa, the largest in the UAE and the largest private medical network in Switzerland.

The enlarged Group had pro-forma revenue of US$4bn for the fiscal period 2014/15, comprising 46% from Switzerland, 31% from South Africa and 23% from the UAE.

It would run 73 hospitals with around 10,200 beds and 35 clinics, and will have nearly 32,000 staff.


View full MDC profile View Profile

Mediclinic International Plc Timeline

Related Articles

healthy gut
July 15 2019
Here we take a look at AIM-listed life sciences group, OptiBiotix Health
cancer scans
July 05 2019
Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers
cancer cell
The San Diego-based company has developed a patented liquid biopsy technology called Target Selector the detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA)

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use